Article
MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated.
Nature communications - 6 Dec 2016
Smida Michal, Fece de la Cruz Ferran, Kerzendorfer Claudia, Uras Iris Z, Mair Barbara, Mazouzi Abdelghani, Suchankova Tereza, Konopka Tomasz, Katz Amanda M, Paz Keren, Nagy-Bojarszky Katalin, Muellner Markus K, Bago-Horvath Zsuzsanna, Haura Eric B, Loizou Joanna I, Nijman Sebastian M B
Abstract excerpt
Lung cancer is the leading cause of cancer deaths, and effective treatments are urgently needed. Loss-of-function mutations in the DNA damage response kinase ATM are common in lung adenocarcinoma but directly targeting these with drugs remains challenging. Here we report that ATM loss-of-function is synthetic lethal with drugs inhibiting the central growth factor kinases MEK1/2, including the FDA-approved drug...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.